• Corpus ID: 19098963

Evodiamine attenuates pressure overload-induced cardiac hypertrophy

  title={Evodiamine attenuates pressure overload-induced cardiac hypertrophy},
  author={Fangfang Li and Yuan Yuan and Ning Zhang and Qing-Qing Wu and Jin Li and Mengqiao Zhou and Zheng Yang and Qi-zhu Tang},
Evodiamine, a traditional Chinese herb Evodia rutaecarpa, has been shown its anti-inflammatory and anti-bacterial properties. However, the role of evodiamine in cardiac hypertrophy and its possible molecular mechanisms remain unclear. Therefore, this study aimed to investigate the effect of evodiamine on cardiac hypertrophy and explore the possible mechanisms. Aortic banding (AB) on mice was performed to induce the models of cardiac hypertrophy. Evodiamine was administered to mice for 7 weeks… 

Figures from this paper

Evodiamine attenuates TGF-β1-induced fibroblast activation and endothelial to mesenchymal transition
Investigation of the effect of evodiamine on fibroblast activation in cardiac fibroblasts and endothelial to mesenchymal transition (EndMT) in human umbilical vein endothelial cells (HUVECs) found that it could prevent cardiac fibrablasts from activation into myofibroblast and protect HUVEC against EndMT.
Re-Purposing Evodiamine as an Anti-CancerDrug: Effects on Migration and Apoptosis
The goal of this study was to determine the feasibility of re-purposing evodiamine as an anti-cancer drug and to test the necessary concentrations to achieve possible clinical results through oral administration.


Puerarin attenuates pressure overload-induced cardiac hypertrophy.
IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
It is demonstrated that IKKi deficiency exacerbates cardiac hypertrophy by regulating the AKT and NF-κB signaling pathway.
Activating Transcription Factor 3 Deficiency Promotes Cardiac Hypertrophy, Dysfunction, and Fibrosis Induced by Pressure Overload
It is suggested that ATF3 plays a crucial role in the development of cardiac hypertrophy via negative regulation of the MEK-ERK1/2 and JNK pathways.
Pretreatment by Evodiamine is Neuroprotective in Cerebral Ischemia: Up-Regulated pAkt, pGSK3β, Down-Regulated NF-κB Expression, and Ameliorated BBB Permeability
Evo protected the brain from ischemic damage caused by pMCAO; this effect may be through upregulation of pAkt, pGSK3β and claudin-5, and downregulation of NF-κB expression.
3,3′-Diindolylmethane Protects against Cardiac Hypertrophy via 5′-Adenosine Monophosphate-Activated Protein Kinase-α2
DIM significantly improves left ventricular function via the activation of AMPKα2 in a murine model of cardiac hypertrophy and protected against cardiac oxidative stress by regulating expression of estrogen-related receptor-alpha (ERRα) and NRF2 etc.
Molecular targets and regulators of cardiac hypertrophy.
Differential expression of lipid metabolism genes in the liver and adipose tissue of mice treated with evodiamine.
The main mechanism of the regulation of body fat deposition by evodiamine is raising energy consumption through reducing body temperature and promoting fat decomposition.
Disruption of Tumor Necrosis Factor Receptor Associated Factor 5 Exacerbates Pressure Overload Cardiac Hypertrophy and Fibrosis
The results suggest that as an intrinsic cardioprotective factor, TRAF5 plays a crucial role in the development of cardiac hypertrophy through the negative regulation of the MEK‐ERK1/2 pathway.
Evodiamine Inhibits Insulin-Stimulated mTOR-S6K Activation and IRS1 Serine Phosphorylation in Adipocytes and Improves Glucose Tolerance in Obese/Diabetic Mice
The results suggest evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.